Fierce Biotech Layoff Tracker 2026: BioCryst ends internal programs; Biogen sheds Apellis R&D roles Read more →

Can We Outrun Cancer's Evolution? Why BrYet Is Targeting Cancer-Specific Phenotypes Read more →

Scribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trials Read more →